PT-141 (Bremelanotide) Real-World Evidence: What Registries and Post-Marketing Data Actually Show

How Bremelanotide Works: The MC4R Mechanism

Bremelanotide activates melanocortin-4 receptors (MC4R) in the central nervous system, a mechanism distinct from every other approved sexual dysfunction therapy. The drug does not act on vascular smooth muscle like PDE5 inhibitors. It targets hypothalamic and limbic circuits involved in sexual desire itself.

The melanocortin system regulates multiple physiological processes, from appetite to pigmentation to sexual arousal. PT-141 is a synthetic cyclic peptide analog of alpha-melanocyte-stimulating hormone (α-MSH). When injected subcutaneously, it crosses the blood-brain barrier and binds MC4R neurons in the medial preoptic area and paraventricular nucleus of the hypothalamus, regions with well-documented roles in sexual motivation 1.

This central mechanism explains two things clinicians observe. First, bremelanotide can increase subjective desire rather than simply facilitating a peripheral arousal response. Second, it produces side effects consistent with hypothalamic activation: nausea (mediated by area postrema MC4R), transient blood pressure elevation, and occasional facial flushing or skin hyperpigmentation. The nausea tends to diminish with repeated dosing in roughly half of affected patients, a pattern consistent with receptor desensitization at the area postrema 2.

Animal studies initially demonstrated that MC4R activation induced penile erection in male rats and lordosis behavior in female rats, findings that drove early clinical investigation of PT-141 in both sexes 3. The drug's development path eventually narrowed to female HSDD after mixed results in male erectile dysfunction trials, though off-label male use persists.

The RECONNECT Trials: The Registration Evidence Base

The two RECONNECT Phase III trials (Study 301 and Study 302) enrolled 1,247 premenopausal women with HSDD and remain the primary controlled evidence supporting bremelanotide's efficacy. Both were randomized, double-blind, placebo-controlled, and ran for 24 weeks of home-based, as-needed dosing.

The co-primary endpoints were changes from baseline in the Female Sexual Function Index-desire domain (FSFI-D) and the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) Item 13 score. Pooled results showed a statistically significant 0.5-point improvement in FSFI-D (on a 1.2-to-6.0 scale) and a 0.7-point reduction in sexual distress compared with placebo 2. These are modest effect sizes. The FDA's own review acknowledged this, but the agency concluded the improvements were clinically meaningful based on patient global impression of change data, where 35% of bremelanotide patients rated themselves "much" or "very much" improved versus 23% on placebo.

Nausea occurred in 40.0% of bremelanotide-treated patients versus 1.3% on placebo. Flushing was reported in 20.3% versus 1.5%. Headache affected 11.3% versus 6.4%. The nausea was typically mild to moderate, peaked within the first few doses, and led to study discontinuation in only 6.3% of the active-treatment group 4.

One critical limitation: RECONNECT excluded women with uncontrolled hypertension or significant cardiovascular disease. This means the trial population does not represent the full range of patients who might receive prescriptions in clinical practice.

Post-Marketing Safety Surveillance: What the FDA Has Tracked

Since approval, the FDA Adverse Event Reporting System (FAERS) has accumulated reports on bremelanotide that largely mirror the trial safety profile, with a few signals worth tracking. The most frequently reported post-marketing adverse events remain nausea, injection site reactions, headache, and flushing 4.

The blood pressure signal deserves particular attention. In RECONNECT, bremelanotide produced transient mean increases of approximately 6 mmHg systolic and 3 mmHg diastolic, peaking about 2-4 hours post-dose and resolving within 12 hours 2. The FDA label carries a warning about this effect, and the drug is not recommended in patients with uncontrolled hypertension or known cardiovascular disease. Post-marketing reports have not revealed unexpected cardiovascular events at a rate exceeding background, but the limited prescribing volume makes this difficult to interpret with confidence.

Skin hyperpigmentation, particularly facial and gingival darkening, appeared in approximately 1% of trial participants and has been reported post-marketing as well. This effect is mechanistically expected given MC4R's role in melanocyte signaling and appears to be slowly reversible after discontinuation 5.

The FDA's Risk Evaluation and Mitigation Strategy (REMS) was not required for bremelanotide, unlike flibanserin (Addyi), which needed a REMS due to interactions with alcohol. This distinction has practical implications for prescribing patterns: bremelanotide does not carry alcohol-interaction contraindications, which may influence patient and clinician preference in some cases.

Real-World Persistence and Utilization Patterns

Pharmacy benefit manager (PBM) data and commercial claims analyses provide the clearest window into real-world bremelanotide utilization, though published peer-reviewed analyses remain scarce. The available evidence suggests a significant gap between trial persistence and real-world continuation rates.

In RECONNECT, approximately 87% of patients completed the 24-week study. Real-world persistence appears substantially lower. IQVIA prescription data reported through mid-2022 indicated modest commercial uptake, with cumulative prescriptions numbering in the low tens of thousands nationally 6. Several factors contribute to the gap between clinical trial completion rates and real-world persistence.

Cost is a primary barrier. Without insurance coverage, Vyleesi carries a list price of approximately $900 per month (at maximum labeled frequency of 8 doses). Many commercial plans do not cover HSDD therapies, or impose prior authorization and step-therapy requirements. Medicare Part D excludes drugs for sexual dysfunction by statute. The manufacturer's patient assistance programs offset some cost burden, but out-of-pocket expense remains a commonly cited reason for discontinuation.

Nausea drives early attrition. Clinicians who prescribe bremelanotide frequently report that patients who tolerate the first 3-5 doses tend to continue. Those who experience significant nausea on initial use often do not refill. Pre-treatment with ondansetron 30 minutes before bremelanotide injection is a common off-label strategy used by prescribers, though no controlled data support this approach.

Self-injection logistics present another barrier. Unlike oral flibanserin (which requires daily dosing but avoids injections), bremelanotide requires subcutaneous self-administration via an autoinjector. Some patients find this acceptable, while others report that the injection ritual reduces spontaneity, a particular concern given that the drug targets desire, an experience many patients associate with spontaneity itself.

Dr. Sheryl Kingsberg, a clinical psychologist and HSDD researcher at University Hospitals Cleveland Medical Center, has noted: "The real-world challenge with bremelanotide isn't efficacy. It's the mismatch between the as-needed injection model and patients' expectations of how desire should feel. The women who do well are the ones who plan for intimacy rather than waiting for spontaneous desire" 7.

Registry Data and Observational Studies

Formal patient registries for bremelanotide remain limited compared with those available for GLP-1 receptor agonists or testosterone replacement therapy. No large-scale, independent post-marketing registry has been published as of mid-2026. The evidence base for real-world effectiveness relies on several smaller data sources.

A post-hoc analysis of RECONNECT open-label extension data, in which patients used bremelanotide for up to 52 weeks, showed that efficacy was maintained over the longer period without new safety signals 8. Mean FSFI-desire scores improved from baseline, and sexual distress continued to decrease. Dropout during the open-label phase was 38%, with nausea and lack of efficacy cited as the two most common reasons.

The International Society for the Study of Women's Sexual Health (ISSWSH) has endorsed both bremelanotide and flibanserin for HSDD treatment and has called for real-world effectiveness registries to better characterize long-term outcomes, combination therapy approaches, and outcomes in populations excluded from RECONNECT (postmenopausal women, women with comorbid depression on SSRIs) 9.

Survey-based studies from sexual medicine clinics suggest that patients who use bremelanotide an average of 2-4 times per month report the highest satisfaction scores, a frequency pattern that differs from the trial protocol (which allowed up to 8 times monthly). This pattern may reflect self-titration: patients reserving the drug for occasions when they most want the effect, rather than using it at every opportunity.

Off-Label Use in Men: What the Evidence Shows

PT-141's origins included male erectile dysfunction research, and off-label male use continues despite limited formal evidence. A Phase IIb trial in men with ED (N=342) showed statistically significant improvements in erectile function versus placebo, particularly in patients who had previously failed PDE5 inhibitors 10. The effect appeared mediated through central arousal rather than peripheral vasodilation, suggesting potential utility in psychogenic ED or as combination therapy with PDE5 inhibitors.

No Phase III trial in men was completed. Palatin Technologies shifted development focus to female HSDD after strategic review. The compounding pharmacy market has filled this gap, with bremelanotide available from compounding pharmacies as a subcutaneous injection for male patients, typically prescribed by sexual medicine specialists and anti-aging clinicians.

Published real-world data on male use is minimal. Case series and clinic-level reports suggest response rates of approximately 50-60% for subjective improvement in erectile function, with nausea as the primary limiting side effect 11. Men who report improved desire rather than strictly mechanical erection quality may be experiencing the drug's central MC4R-mediated effect on motivation and arousal, consistent with its mechanism.

The Endocrine Society and American Urological Association have not endorsed bremelanotide for male ED in current guidelines. Clinicians prescribing off-label should document the rationale and discuss the limited evidence base with patients 12.

Bremelanotide vs. Flibanserin: Real-World Comparisons

Two FDA-approved HSDD therapies exist. Head-to-head trial data do not. Real-world comparisons rely on indirect evidence, prescribing patterns, and patient preference data from clinical surveys.

Flibanserin (Addyi) requires daily oral dosing and carries alcohol contraindications through its REMS program. Bremelanotide is as-needed and has no alcohol interaction. In practice, this distinction matters. The REMS requirement for flibanserin created prescribing friction that limited uptake. Bremelanotide's as-needed model avoids daily medication burden but introduces injection logistics.

Prescription volume data suggest that neither drug has achieved large-scale commercial success. A 2021 analysis published in the Journal of Sexual Medicine estimated that combined HSDD therapy prescriptions (flibanserin plus bremelanotide) reached fewer than 10,000 active patients nationally at any given time, a fraction of the estimated 6 million premenopausal women meeting HSDD diagnostic criteria in the United States 6.

Dr. Irwin Goldstein, director of San Diego Sexual Medicine, has stated: "Both approved HSDD treatments work through different mechanisms, and patient preference varies. Some women prefer the predictability of daily flibanserin. Others prefer the on-demand flexibility of bremelanotide. The clinical challenge is matching the right drug to the right patient, and many clinicians still don't screen for HSDD at all" 13.

The treatment gap between diagnosed HSDD prevalence and actual prescribing volume reflects multiple systemic barriers: clinician unfamiliarity with HSDD pharmacotherapy, insurance non-coverage, stigma around female sexual dysfunction, and patient reluctance to initiate conversations about desire. These barriers are not unique to bremelanotide but affect the entire HSDD therapeutic class.

Emerging Research Directions

Several areas of bremelanotide research are active or anticipated as of 2026. Combination protocols pairing bremelanotide with testosterone therapy in postmenopausal women represent one area of clinical interest, though no controlled trials have been published. The rationale is that testosterone addresses baseline androgen deficiency while bremelanotide provides acute, on-demand desire augmentation.

Investigation of intranasal bremelanotide formulations could address the injection barrier. Early pharmacokinetic work suggested that intranasal delivery achieves adequate CNS penetration, though the original intranasal program was paused due to blood pressure concerns at higher doses 14. Whether reformulation at lower intranasal doses could achieve efficacy with acceptable hemodynamic effects remains an open question.

MC4R agonism is also being explored in other sexual dysfunction contexts, including SSRI-induced sexual dysfunction, a common and often treatment-limiting side effect of antidepressant therapy. A small open-label study suggested bremelanotide might partially reverse SSRI-associated low desire, but the sample size (N=18) precludes definitive conclusions 15.

The 2019 ISSWSH process of care algorithm for HSDD recommends that pharmacotherapy be considered when psychoeducation and sex therapy alone are insufficient, and that the choice between flibanserin and bremelanotide should be individualized based on patient preference, comorbidities, and tolerability considerations 9. The 8-dose monthly cap on the FDA label is based on clinical trial design limits rather than identified toxicity at higher frequencies, and some clinicians report patients using the drug at lower frequencies with satisfactory outcomes.

Clinicians initiating bremelanotide should obtain a baseline blood pressure reading, counsel patients about transient nausea (which typically attenuates after 3-5 uses), and schedule a follow-up assessment at 8-12 weeks to evaluate both efficacy and tolerability before continuing long-term prescriptions.